Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.96 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.96 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.96 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.96 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.96 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.96 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.96 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.96 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.96 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.96 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.83 |
| ▸ | MAPT | P10636 | 3/20 | 0.83 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.83 |
| ▸ | LMNA | P02545 | 2/20 | 0.83 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9352420 | 0.98 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL6604478 | 0.98 | HDAC1 (0.92) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL3381106 | 0.98 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL3383102 | 0.98 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL3378075 | 0.98 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL9356269 | 0.98 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL7824358 | 0.98 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL9663087 | 0.98 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL503304 | 0.95 | HDAC1 (0.88) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL6608564 | 0.93 | HDAC1 (0.84) | HDAC1HDAC8HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1933 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3624854-B1 | PROTEIN-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCERS | UNIV STRASBOURG (FR) | 2026-04-15 | — | — | EP | claimed |
| US-20260083866-A1 | COMPOSITIONS TARGETING ENDOTHELIAL CELLS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-03-26 | — | — | US | claimed |
| US-20260069697-A1 | METHOD OF TREATING CANCER | INTENSITY THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | claimed |
| EP-4658676-A2 | ANTI-CDH17 ANTIBODIES AND USE OF THE SAME | Bighat Biosciences, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4635516-A2 | ANTI-EDB ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | Pfizer Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4633681-A1 | AURISTATIN LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-10-22 | — | — | EP | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| CN-120078904-A | Conjugates of cytotoxic drugs and prodrug forms of the conjugates | 辛迪维亚公司 | 2025-06-03 | — | — | CN | claimed |
| US-6861550-B2 | Polyhydroxyalkanoate containing 3-hydroxybenzoylalkanoic acid as monomer unit, and method for producing the same | CANON KABUSHIKI KAISHA (JP) | 2005-03-01 | — | — | US | claimed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089470-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089415-A2 | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004045647-A1 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD (AU) | 2004-06-03 | — | — | WO | claimed |
| US-6635782-B2 | Using microorganism in culture media; polylactones; biodegradable, melt processability | CANON KABUSHIKI KAISHA (JP) | 2003-10-21 | — | — | US | claimed |
| US-20030100084-A1 | Polyhydroxyalkanoate containing 3-hydroxybenzoylalkanoic acid as monomer unit, and method for producing the same | CANON KABUSHIKI KAISHA (JP) | 2003-05-29 | — | — | US | claimed |
| US-20020160467-A1 | Polyhydroxyalkanoate and manufacturing method thereof | CANON KABUSHIKI KAISHA (JP) | 2002-10-31 | — | — | US | claimed |
| EP-1188782-A2 | Polyhydroxyalkanoate and manufacturing method thereof | CANON KABUSHIKI KAISHA (JP) | 2002-03-20 | — | — | EP | claimed |
| EP-1130042-A2 | Polyhydroxyalkanoate containing 3-hydroxybenzoylalkanoic acid as monomer unit, and method for producing the same | CANON KABUSHIKI KAISHA (JP) | 2001-09-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083866-A1 | COMPOSITIONS TARGETING ENDOTHELIAL CELLS AND USES THEREOF | FLT1, VCAM1, FLT4 | HDAC1 4452/4885HDAC8 4327/4885HDAC3 4696/4885 |
| US-20260069697-A1 | METHOD OF TREATING CANCER | PBK, GZMB, KLRK1 | HDAC1 4560/4885HDAC8 2483/4885HDAC3 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.